| HS Code | 100899 |
| Product Name | LACTEL 50:50 DL-PLG (B6017-1) Biomedical PLGA Copolymer |
| Brand | LACTEL |
| Product Number | B6017-1 |
| Chemical Name | Poly(D,L-lactide-co-glycolide) |
| Abbreviation | PLGA |
| Cas Number | 26780-50-7 |
| Monomer Ratio | 50:50 D,L-lactide:glycolide |
| Stereochemistry | D,L-lactide (racemic) |
| Inherent Viscosity | 0.15-0.25 dL/g |
| Molecular Weight | 10,000-15,000 Da |
| Appearance | White to off-white powder |
| Form | Powder |
| Solubility | Soluble in dichloromethane, chloroform, and 1,1,1,3,3,3-hexafluoroisopropanol |
| Glass Transition Temperature | 45-50 °C |
| Storage Conditions | Store at -20 °C, desiccated, protected from moisture |
| Degradation Behavior | Hydrolytically biodegradable |
| Biocompatibility | Biocompatible and biodegradable |
| Density | 1.2-1.3 g/cm³ |
As an accredited LACTEL 50:50 DL-PLG (B6017-1) Biomedical PLGA Copolymer factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | LACTEL 50:50 DL-PLG (B6017-1) Biomedical PLGA Copolymer is supplied as 1 g in a sealed glass bottle. |
| Container Loading (20′ FCL) | 20′ FCL container loading for LACTEL 50:50 DL-PLG (B6017-1) Biomedical PLGA Copolymer: dry, temperature-controlled, secure, compliant, and fully documented shipment. |
| Shipping | LACTEL 50:50 DL-PLG (B6017-1) is shipped as a non-hazardous, non-regulated material. No UN number, hazard class, or packing group applies. It is packaged in sealed, moisture-resistant containers and transported at ambient temperature. Protect from heat, light, and moisture. Store at -20°C upon receipt. Standard laboratory transport is suitable. |
| Storage | Store LACTEL 50:50 DL-PLG (B6017-1) Biomedical PLGA Copolymer in its original, tightly sealed container at –20°C, desiccated and protected from moisture, light, and heat. Handle under dry, inert gas if possible. Before opening, allow the vial to equilibrate to room temperature to prevent condensation. Avoid repeated freeze–thaw cycles, prolonged ambient humidity, and use promptly once opened. |
| Shelf Life | Store at -20°C in a tightly closed container, protected from moisture and light; stable for 2 years under these conditions. |
The LACTEL 50:50 DL-PLG (B6017-1) grade with a low inherent viscosity specification of 0.15–0.25 dL/g in hexafluoroisopropanol is introduced into the dispersed organic phase of an emulsification-based microsphere line. In o/w or w/o/w manufacturing, the copolymer is dissolved in dichloromethane at 10–20% w/v; the drug:polymer mass ratio is set from 1:5 to 1:20 depending on peptide or small-molecule potency, burst-release ceiling, and injection-volume constraints. The organic phase is emulsified into a continuous aqueous phase containing polyvinyl alcohol at 0.5–2.0% w/v under high-shear rotor-stator agitation or in-line microfluidics. During solvent extraction, the dichloromethane flux across the droplet interface determines pore formation and drug migration toward the surface; a fast extraction at 25–35°C and reduced pressure can collapse the matrix shell, while a slow extraction can produce high porosity but can also increase surface-associated drug. Lower organic-phase viscosity compared with high-IV PLG reduces the shear required to reach target droplet size, but narrows the solvent-extraction window because smaller droplets lose dichloromethane more quickly. Production-scale equipment of concern includes jacketed stirred vessels with bottom-mount high-shear mixers, in-line Silverson or IKA rotor-stator units, and continuous centrifugal classifiers because batch-to-batch particle-size drift is observed if the dispersed phase viscosity changes with atmospheric water uptake. The terminal product type is a sterile lyophilized injectable microsphere powder, typically sieved to 20–60 µm for intramuscular or subcutaneous long-acting depots. Compliance is anchored to FDA 21 CFR 210/211 for finished drug product cGMP, ICH Q3C(R8) for residual dichloromethane with a Class 2 concentration limit of 600 ppm, USP <71> for sterility, USP <85> for bacterial endotoxins, and ISO 10993-1:2018 for the biological evaluation program. In vitro release and polymer degradation testing follow ISO 13781:2017 for resorbable polylactide-based copolymers where applicable to implantable depots.
Electrospun tissue regeneration scaffolds using the 50:50 DL-PLG low-IV grade require solution concentration compensation because low chain entanglement shifts the stable-jet window upward in hexafluoroisopropanol. A workable solution composition is 10–25% w/v copolymer in hexafluoro-2-propanol or a dichloromethane/dimethylformamide mixture; a 15% w/v copolymer loading in hexafluoro-2-propanol is a common starting condition for a uniform jet. The production process deposits fibers onto a grounded rotating drum or plate collector through a multi-nozzle linear array; applied voltage is maintained at 15–30 kV, solution flow rate at 0.5–2.0 mL/h per nozzle, tip-to-collector distance at 10–20 cm, and relative humidity below 40% to prevent premature fiber fusion and bead formation. On production lines, nozzle plugging occurs when the low-IV solution is held too long in the reservoir without cooling; this changes the Rayleigh jet stability and produces intermittent bead-on-string morphology. The terminal product types are implantable fibrous scaffolds and wound-contact mats with fiber diameters from 200 nm to 2 µm after vacuum drying to remove residual hexafluoroisopropanol. Compliance for a tissue-contact scaffold is managed under ISO 13485:2016 quality systems, ISO 10993-5:2009 for in vitro cytotoxicity, ISO 10993-10:2010 for skin sensitization, and ISO 10993-1:2018 for selection of end-use biological tests; residual hexafluoroisopropanol documentation follows ICH Q3C(R8) for residual solvent control.
Nanoparticle drug delivery lines use the same low-IV 50:50 DL-PLG in a solvent-displacement process rather than an emulsification route. The copolymer is dissolved at 1–10 mg/mL in a water-miscible organic phase such as acetone, acetonitrile, or tetrahydrofuran; the aqueous phase contains a surfactant or steric stabilizer at 0.1–1.0% w/v, commonly poloxamer 188 or polyvinyl alcohol. The formulation addition ratio is frequently expressed as drug:polymer from 1:2.5 to 1:10, with total solids below 2% w/v to avoid aggregation. Production is by rapid solvent displacement under controlled mixing; the organic phase is injected into the aqueous phase at a defined rate, or both phases are combined in a microfluidic tee or hydrodynamic flow-focusing channel to maintain particle size below 100 nm. Scale-up equipment includes high-precision syringe pumps, tangential flow filtration with 100 kDa or 300 kDa regenerated cellulose membranes for purification, and lyophilizers with controlled shelf temperature below the collapse temperature of the added cryoprotectant. The terminal product type is a lyophilized nanoparticle powder for parenteral oncology or neurology applications. Compliance includes ISO 10993-5:2009 for cytotoxicity, USP <71> for sterility, USP <85> for endotoxin, USP <787> for subvisible particulate matter in therapeutic protein injections, and ICH Q3C(R8) for residual acetone or acetonitrile.
| Application line | Referenced standard or regulation | Control focus | Numeric target where standardized |
|---|---|---|---|
| Microsphere long-acting depot | ICH Q3C(R8) | Residual dichloromethane | 600 ppm Class 2 limit |
| Electrospun tissue scaffold | ISO 10993-5:2009 | In vitro cytotoxicity | Non-cytotoxic grade in validated assay |
| Parenteral nanoparticle formulation | USP <787> | Subvisible particulate matter | Reported particle count per monograph |
| In situ forming depot | ISO 10993-6:2016 | Local effects after implantation | Histopathology score at implant site |
| Solvent-cast film | ASTM D882-12 | Tensile properties of thin film | Film-specific stress-strain curve |
| Melt-extruded rod | ISO 10993-6:2016 | Local tissue reaction | Histopathology score at implant site |
Injectable in situ forming depots based on phase inversion are prepared by dissolving the 50:50 DL-PLG low-IV grade in N-methyl-2-pyrrolidone at 30–50 wt%, with the active pharmaceutical ingredient co-dissolved or dispersed as a micronized suspension if the dose exceeds the solvent solubility. The liquid formulation is filled into single-dose vials or prefilled syringes under low-moisture conditions; at the point of injection, N-methyl-2-pyrrolidone diffuses into surrounding tissue, water ingresses into the injected liquid, and the copolymer precipitates as a solid or semi-solid implant. The phase inversion rate is controlled by the solvent:water ratio and polymer concentration; formulations below 30 wt% can fragment or produce unduly fast release, while formulations above 50 wt% may exceed practical injection force through 21-gauge needles. The terminal product type is an injectable in situ forming depot for extended-release small molecules or peptides in subcutaneous or intramuscular tissue. Compliance is governed by ISO 10993-6:2016 for local effects after implantation, USP <85> for bacterial endotoxins, USP <71> for sterility, and ICH Q3C(R8) for residual solvent documentation; N-methyl-2-pyrrolidone is listed as a Class 2 solvent with a permitted daily exposure limit of 5.3 mg/day under ICH guidance, although product-specific toxicological qualification applies when N-methyl-2-pyrrolidone is an intentional excipient rather than a residual solvent.
For continuous solvent-cast coating lines, the low-IV 50:50 DL-PLG grade is selected when high solution clarity and low yield stress are required. The copolymer is dissolved at 5–15% w/v in dichloromethane, ethyl acetate, or a dichloromethane/ethanol mixture; plasticizers or pore formers such as polyethylene glycol 400 may be added at 5–20% w/w relative to PLGA to adjust film flexibility and water uptake. The solution is cast onto a release liner or directly onto a medical device using knife-over-roll or slot-die coating; drying is staged from 15°C to 35°C under laminar airflow to prevent skin-over and solvent entrapment. Residual solvent levels are driven to below ICH limits, typically requiring vacuum drying at 40°C for low-molecular-weight PLG grades because solvent retention increases near the glass transition of the low-IV copolymer. The terminal product types are bioresorbable adhesion barrier films, drug-eluting coatings, or thin implant layers. Compliance includes ISO 10993-5:2009 for cytotoxicity, ISO 10993-10:2010 for sensitization, ISO 10993-11:2017 for systemic toxicity, and tensile testing per ASTM D882-12 for thin polymer films.
When hot-melt extrusion is selected for high-dose implant rods, the 50:50 DL-PLG low-IV grade is compounded without solvent residues. The drug:polymer mass ratio is typically 1:10 to 1:20; triethyl citrate or polyethylene glycol 400 may be added at 5–15 wt% to lower melt viscosity and reduce shear heating. Compounding is performed in a co-rotating twin-screw extruder with an L/D ratio of 25:1 to 40:1, with barrel zone temperatures between 90°C and 130°C and screw speeds below 200 rpm to limit autocatalytic hydrolytic degradation. The extrudate is pelletized, dried below 0.5% residual moisture, and either injection-molded or extruded into rods for subcutaneous implantation. Published data for the exact low-IV grade in hot-melt extrusion are limited; process development must confirm molecular weight retention by gel permeation chromatography and residual monomer content before scale-up. The terminal product type is a sterile single-use implant rod or cylinder. Compliance includes ISO 10993-6:2016 for local tissue reaction, USP <71> for sterility, USP <85> for bacterial endotoxins, and ICH Q3C(R8) for any residual processing aids.
Competitive LACTEL 50:50 DL-PLG (B6017-1) Biomedical PLGA Copolymer prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618136850665 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8618136850665
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
LACTEL 50:50 DL-PLG (B6017-1) is an acid-terminated, amorphous poly(DL-lactide-co-glycolide) copolymer supplied for biomedical polymer processing where relatively rapid and predictable resorption is required. The nominal lactide:glycolide molar ratio is 50:50. The manufacturer’s specification places inherent viscosity between 0.55 dL/g and 0.75 dL/g, measured at 0.5 g/dL in chloroform at 30 °C using dilute-solution viscometry aligned with ISO 1628-1:2021. Differential scanning calorimetry by ASTM D3418-15 records a glass transition temperature between 45 °C and 50 °C, with no crystalline melting endotherm because the DL-lactide comonomer disrupts chain order. Residual moisture is controlled at or below 0.5% w/w when tested by ISO 15512:2019. The supplied form is white to off-white granules. The resin is soluble in dichloromethane, tetrahydrofuran, ethyl acetate, acetone, dimethylformamide, and N-methyl-2-pyrrolidone; it is insoluble in water, methanol, ethanol, and aliphatic hydrocarbons. These properties position B6017-1 for solvent-based microsphere and nanoparticle fabrication, electrospinning, solvent casting, and controlled low-shear melt processing. Because the copolymer is a hydrolytically degradable polyester, batch-to-batch molecular weight distribution and residual oligomer content influence release kinetics; the certificate of analysis is therefore the authoritative batch-specific dataset. Published data for this specific configuration are limited once a process departs from standard oil-in-water emulsion or solvent-casting workflows.
Terminal-group chemistry is the first variable that separates B6017-1 from other 50:50 DL-PLG products of equivalent inherent viscosity. In the manufacturer’s nomenclature for this family, the -1 suffix identifies an acid-terminated product, while ester-capped analogues are designated with a -2 suffix. Acid-terminal groups increase the equilibrium moisture sorption of the amorphous matrix and provide additional carboxyl species that catalyse ester hydrolysis. Under in vitro testing in phosphate-buffered saline at 37 °C and pH 7.4 as described in ASTM F1635-16, an acid-terminated 50:50 PLGA typically shows a shorter induction period before measurable mass loss than an ester-capped analogue of the same lactide:glycolide ratio. The practical consequence is faster initial release from drug-loaded devices and earlier bioresorption. Ester-capped material is used when a longer lag phase or lower initial acidity at the implant–tissue interface is desired. The acid-terminal-group difference is not cosmetic; changing from B6017-1 to an ester-capped lot of the same nominal composition can shift the degradation timeline and should be treated as a formulation change under ISO 13781:2017 because degradation kinetics, drug-release profile, and the distribution of water-soluble oligomers may diverge.
Solvent selection for B6017-1 is constrained less by the copolymer ratio than by the amorphous character and moderate solution viscosity. In microsphere fabrication, dichloromethane remains the dominant dispersed phase because its boiling point near 39.6 °C and low water miscibility permit rapid extraction into an aqueous continuous phase containing poly(vinyl alcohol). Ethyl acetate and acetone are used as lower-toxicity alternatives, but their higher water miscibility changes the phase-separation pathway and can produce porous or irregular particles if the solvent/water ratio and quench temperature are not tightly controlled. For a single oil-in-water emulsion, the organic phase for B6017-1 is commonly formulated at 5–15% w/w polymer; above approximately 20% w/w, the dynamic viscosity of the organic phase rises enough to alter droplet breakage in a rotor–stator homogenizer. The resulting particle size distribution becomes more sensitive to tip speed, continuous-phase stabilizer concentration, and vessel geometry than to the intrinsic polymer specification. These process variables must be fixed before comparative batch analysis is attempted.
The degradation of B6017-1 follows bulk erosion rather than surface erosion. Water uptake occurs throughout the polymer matrix because water diffusion is faster than ester hydrolysis at the processing temperatures used for microparticles and films. Molecular weight declines before significant mass loss; published data for comparable 50:50 PLGA grades show that weight-average molecular weight can fall below 10% of its initial value while dry mass retention remains comparatively high, after which mass loss accelerates and soluble lactic and glycolic acid oligomers are released. In phosphate-buffered saline at 37 °C and pH 7.4, literature values for 50:50 PLGA with inherent viscosities in the 0.55–0.75 dL/g range often place the onset of measurable mass loss between 4 weeks and 8 weeks; the exact interval for B6017-1 depends on specimen thickness, porosity, buffer exchange rate, and residual oligomer content. Accelerated in vitro tests using elevated temperature or reduced pH shorten the observation period but must be interpreted through ASTM F1635-16 because the mechanism can shift from bulk hydrolysis to acid-catalysed chain scission that does not scale linearly with time. In vivo performance can be faster than buffer-derived predictions because local enzymatic activity, lipid exposure, and acidic microenvironments influence resorption. A change in terminal group, copolymer ratio, or inherent viscosity outside the qualified range should therefore be evaluated as a new material, not as a minor supplier adjustment.
Hot-melt extrusion of B6017-1 is feasible only when residual moisture is driven below the specification limit and the extruder is configured for low shear. The amorphous resin softens above its glass transition and can be conveyed at barrel temperatures between 120 °C and 150 °C, but the residence time must be limited because ester linkages undergo thermal hydrolysis in the presence of moisture and because local shear heating can accelerate chain scission. A co-rotating twin-screw extruder with an L/D ratio of 25:1 to 40:1, a nitrogen-purged feed zone, and an atmospheric vent has been used for comparable PLGA grades; the screw profile should avoid high-energy kneading sections that raise melt temperature above 180 °C. Under those conditions, torque can remain low because the material is amorphous, but melt strength is limited and strand pelletizing can be more difficult than with semicrystalline poly(L-lactide). Published data for this specific configuration are limited, and extrusion trials with a small batch are required before scaling to production. When solvent-based processing is used instead, the drying step can be omitted if anhydrous solvents and sealed glassware are maintained; otherwise, pre-drying under vacuum near 35–40 °C for 24–48 h is common before melt processing.
Terminal sterilization of B6017-1 by gamma irradiation can reduce molecular weight and broaden the molecular weight distribution through free-radical chain scission and oxidative degradation. A routine absorbed dose of 25 kGy delivered at ambient temperature may shift the inherent viscosity downward and increase the proportion of low-molecular-weight oligomers; therefore, radiation dose mapping and post-irradiation viscometry should be performed before release. Irradiation at reduced temperature, such as with dry ice in the irradiation container, is used for some resorbable polyesters to limit radical mobility, but the effect on B6017-1 must be confirmed experimentally because the amorphous matrix has a different free-volume response than semicrystalline polylactide. Validation follows ISO 11137-1 and ISO 11137-2, with dose setting based on product density, packaging, and bioburden rather than polymer specification alone. If gamma irradiation is not acceptable, ethylene oxide remains a common alternative for moisture-sensitive resorbable polymers, but residue limits and aeration time must be considered; dry-heat sterilization is generally unsuitable because extended exposure above the glass transition can induce thermal degradation and flow. The selection of terminal sterilization mode should be finalized before formulation development because sterilization-induced molecular weight loss alters release rate as strongly as a change in copolymer ratio.
For injectable microsphere or nanoparticle workflows, B6017-1 is typically dissolved in a volatile organic phase and emulsified or nanoprecipitated into an aqueous stabilizer solution. The particle size depends less on the 50:50 ratio than on the oil/water phase ratio, homogenization energy, and stabilizer molecular weight. A low-shear overhead impeller operating at 300–800 rpm may produce particles in the tens of micrometers when the organic phase is 10% w/w polymer; high-shear rotor–stator dispersion above 3,000 rpm is required for smaller mean diameters. Increasing the poly(vinyl alcohol) concentration in the continuous phase reduces coalescence but can leave residual stabilizer at the particle surface, changing the early burst release. The acid terminal groups in B6017-1 also increase particle hydrophilicity relative to ester-capped material, which can reduce particle aggregation in aqueous suspension but may raise initial water uptake. Because residual dichloromethane is toxicologically limited, solvent removal by extraction or evaporation must be followed by vacuum drying at room temperature or slightly above, with residual solvent assayed before further processing. Published data for this specific configuration are limited where solvent extraction is replaced by supercritical carbon dioxide or microfluidic precipitation, and those routes require separate qualification.
Storage temperature and moisture exposure control degradation before processing. B6017-1 should be stored in sealed containers under an inert gas at −20 °C or lower when long-term stability is required. Before opening, the container should be equilibrated to room temperature to prevent condensation on the granule surface. Once opened, the remaining material should be backfilled with nitrogen or argon and returned to frozen storage as soon as possible. In facilities where relative humidity exceeds 60%, exposure to ambient air should be limited to minutes, not hours, because water uptake by the acid-terminated copolymer is sufficient to initiate hydrolysis during later melt processing. Vacuum drying at 35–40 °C for 24–48 h lowers residual moisture, but over-drying by prolonged exposure above 50 °C can cause particle aggregation and molecular weight loss. The drying step should therefore be linked to a moisture test rather than a fixed cycle when a new bulk container is opened. These operational boundaries are especially relevant for acid-terminated resin because the terminal carboxyl groups increase hygroscopicity relative to ester-capped 50:50 PLGA.
| Parameter | Typical value or limit | Method designation |
|---|---|---|
| Lactide:glycolide molar ratio | 50:50 | 1H NMR (manufacturer method) |
| Inherent viscosity | 0.55–0.75 dL/g | ISO 1628-1:2021; 0.5 g/dL in chloroform at 30 °C |
| Glass transition temperature | 45–50 °C | ASTM D3418-15 |
| Moisture | ≤ 0.5% w/w | ISO 15512:2019 |
| Physical form | White to off-white granules | Visual inspection / certificate of analysis |
| Recommended storage | −20 °C or lower, inert gas | Manufacturer certificate of analysis |
Material qualification of B6017-1 for a drug-device or resorbable implant application typically begins with identity by nuclear magnetic resonance or Fourier-transform infrared spectroscopy, followed by inherent viscosity determination using ISO 1628-1:2021, thermal analysis by ASTM D3418-15, and moisture determination by ISO 15512:2019. Biological evaluation is conducted under ISO 10993-1:2018, with the endpoint matrix determined by intended use and contact duration. In vitro degradation studies use ASTM F1635-16; for a PLGA resin intended for surgical implants, ISO 13781:2017 provides the specification framework for bulk resin, test frequency, package labelling, and supplied information. A change of terminal group, copolymer ratio, or inherent viscosity outside the qualified range should be treated as a design change under ISO 13485:2016 because it may shift the degradation curve, release profile, and local tissue response. These standards do not by themselves clear a finished device; they anchor the raw-material and degradation-test data that support the design history file.
Compared with 75:25 and 85:15 DL-PLG, B6017-1 is selected when shorter resorption time and faster drug release are required. The higher glycolide content in a 50:50 copolymer increases chain hydrophilicity and acid generation, which accelerates bulk hydrolysis. In contrast, 75:25 PLGA typically degrades more slowly and 85:15 PLGA is slower still under equivalent conditions. Relative to poly(L-lactide), B6017-1 is amorphous and therefore avoids the crystalline residues that can release particulate debris late in degradation; this is an advantage in soft-tissue applications but also means the material has lower modulus and cannot be oriented into high-strength fibers. Compared with low-inherent-viscosity 50:50 DL-PLG grades in the 0.05–0.15 dL/g range, B6017-1 yields higher solution viscosity and longer mechanical retention, but it may require lower organic-phase concentration and higher shear input to achieve the same particle size. These distinctions should be mapped to the intended release duration and fabrication route before a specification is frozen.
Operational incompatibilities should be respected. B6017-1 is not stable in strongly alkaline aqueous media, where rapid saponification of ester bonds shortens the degradation window; strongly acidic processing environments can also accelerate chain scission and produce uncontrolled viscosity loss. The resin should not be combined with amine-based additives that catalyse transesterification or aminolysis unless compatibility is demonstrated, because premature chain scission can occur during compounding. Residual water and protic solvents should be excluded from melt-processing feed streams. When a formulation requires a sustained-release depot, the acid terminal groups of B6017-1 may produce a more hydrophilic matrix than ester-capped resin, and the burst phase may increase if the drug is water-soluble and concentrated near the particle surface. These limitations do not make the material unsuitable; they define the processing boundary within which the 50:50 composition and acid-terminal-group chemistry are predictable.